At a glance
Shield Therapeutics is a commercial stage specialty pharmaceutical company.
Delivering innovative speciality pharmaceuticals to address significant unmet needs in the treatment of iron deficiency and hyperphosphatemia.
Our lead product Accrufer®/Feraccru® is a novel, stable, non-salt based oral therapy and is approved in the United States, European Union, UK and Switzerland for the treatment of iron deficiency with or without anaemia in adults.
In Europe the product is marketed as Feraccru® with commercialisation led by Norgine BV. In the USA the product is marketed as Accrufer®.
We also have an exclusive licence agreement with ASK Pharm who will lead development and commercialisation in China, Hong Kong, Macau and Taiwan.